Ukrainian biotechnology company Biopharma, owned by Kostiantyn Yefymenko, continues to expand its production capacity and international presence. The company is preparing to launch a new plant in Uzhhorod as early as September 2026, is building a large facility in Romania with a planned launch in 2027, and is considering further expansion in Latin American countries.
Biopharma President Kostiantyn Yefymenko told Interfax-Ukraine.
According to him, the launch of the plant in the Romanian city of Arad is scheduled for December 2027. Construction of the production building has already been completed, and the company expects to finish connecting engineering utilities by September. A filling line has also been ordered, while contracts for the supply of reactor and other technological equipment are expected to be signed by the end of June.
The Romanian project will be implemented in four phases. Investment in the first phase of the facility will amount to €85 million. Total investment in the new production sites in Uzhhorod and Arad is estimated at approximately $500 million.
At the same time, the company is completing construction of a new plant in Uzhhorod, where the first phase of a facility for the production of pharmaceutical and immunobiological medicines with a full cycle of donor blood plasma processing is expected to be launched in September 2026. To date, €67 million has already been invested in the project, while the cost of the first phase is €75 million.
Once it reaches design capacity, the Uzhhorod plant will be able to process up to 1.5 million liters of blood plasma per year, roughly twice the company’s current production volume in Bila Tserkva. The Romanian project will be even larger, with capacity expected to be approximately twice that of the Uzhhorod facility.
According to Yefymenko, the company is not focusing on a single site and is developing all key projects simultaneously. The Bila Tserkva plant remains the flagship facility, while the new production sites are expected to support further business growth and strengthen the company’s position in international markets.
Expanding the company’s geographic presence is one of its strategic objectives. In addition to Europe and the Middle East, Biopharma is actively working to enter Latin American markets. In particular, the company has already registered its albumin medicine in Brazil, opening opportunities for further sales development in the region.
“Our seventh place in Europe does not satisfy us. We want to move higher — and for that we need scale,” Yefymenko said.
Biopharma is one of the largest producers of blood plasma-derived medicines in Eastern Europe. The company specializes in plasma collection and the production of immunobiological medicines. In 2019, part of the company’s business was acquired by German pharmaceutical group Stada, while the Ukrainian shareholders retained the production of donor plasma-derived medicines at the facility in Bila Tserkva.
